• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Erythorbic Acid (Molecular Formula:C₆H₈O₆)
Sodium Erythorbate(Molecular Formula:C₆H₇NaO₆·H₂O)
water filter
WATER FILTER FOR WATER PURIFIER
DUST BAG
Small dust filter

Orchid Pharma gets EIR from US FDA

expressbpdJanuary 09, 2018

Tag: FDA , Orchid Pharma

Orchid Pharma has received Establishment Inspection Report (EIR) from the US health regulator for its Chennai facility. The company has received the EIR from the United States Food and Drug Administration (US FDA) on successful inspection closure for the post-marketing adverse drug experience reporting inspection (PADE) conducted at Nungambakkam, Chennai facility, Orchid Pharma said in a BSE filing.

The facility was inspected by US FDA in the month of June, 2017, it added. As per the US FDA, after the completion of an inspection of a facility, an EIR is issued to a company detailing inspectional findings.

Previous:VSASL imaging can detect placental perfusion abnormalities in foetal CHD

Next:FDA grants fast-track designation to malaria drug Tafenoquine

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Orchid Pharma gets EIR from US FDA | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

99% up, DMF, FDA (zero defect) Emtricitabine 143491-57-0

99% up, DMF, FDA (zero defect) Emtricitabine 143491-57-0
Vitamine B12 (FDA)

Vitamine B12 (FDA)
9,9-Bis(4-aminophenyl) Fluorene (FDA)

9,9-Bis(4-aminophenyl) Fluorene (FDA)
Mitomycin ( FDA)

Mitomycin ( FDA)
Vinorelbine tartrate (FDA)

Vinorelbine tartrate (FDA)
Irinotecan Hcl trihudrate (FDA)

Irinotecan Hcl trihudrate (FDA)
filter integrity testing fda guidelines

filter integrity testing fda guidelines
Cyclosporin A (FDA)

Cyclosporin A (FDA)
High quality Stability Chamber(FS/CFS Series:FDA)

High quality Stability Chamber(FS/CFS Series:FDA)
Ramantadine( FDA)

Ramantadine( FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service